All articles tagged with #universal vaccine
A nasal spray vaccine, GLA-3M-052-LS+OVA, protected mice against SARS-CoV-2 and other coronaviruses, guarded against certain bacteria, and reduced allergy-related lung symptoms, by engaging both innate and adaptive immunity; with three doses, it lowered lung viral loads and sped up immune responses, and human trials could begin with a target availability in 5–7 years if results translate to people.
Scientists are pursuing a universal flu vaccine that would protect against many influenza strains by targeting conserved parts of the virus; multiple candidates are in trials using approaches such as focusing the immune response on the virus's stable cone of haemagglutinin, exposing fixed regions by presenting thousands of HA variations, blocking neuraminidase, stimulating T cells, or nasal delivery, and some work also explores AI-assisted strain selection. While a true universal vaccine may take years, interim gains include more durable protection and higher-dose shots for older adults, with experts optimistic about improvements within about five to ten years.
A nasal vaccine candidate that trains frontline lung immunity shows promise in mice for broad protection against multiple respiratory infections (cold viruses, flu, and COVID) by boosting alveolar macrophages and T cells rather than targeting a single pathogen; it may also dampen allergic reactions. Human safety and efficacy remain unproven, and the best-case path to a human-ready vaccine is five to seven years, with protection in mice lasting up to about three months and many unknowns, including effects in older adults and on DNA viruses.
Stanford Medicine researchers have developed a nasal spray vaccine that activates the lungs’ innate immune system to provide months-long protection against a broad range of respiratory threats—including SARS-CoV-2, other coronaviruses, bacterial pneumonia pathogens, and even house dust mite allergens—in mice. If safety and efficacy are shown in humans, the approach could reduce the need for multiple yearly vaccines and idea of rapid protection during outbreaks, with Phase I trials moving forward and an estimated 5–7 years before potential availability.
A Stanford-led study describes an intranasal “universal vaccine” that activates the innate immune system to provide at least three months of protection in mice against SARS-CoV-2, other coronaviruses, and bacteria causing respiratory infections, while also dampening allergic responses. If safe and effective in humans, it could become a winter-wide first line of defense against diverse respiratory diseases.
Stanford Medicine researchers report an intranasal vaccine that activates innate and adaptive immunity to provide months-long protection in mice against a broad spectrum of respiratory threats—SARS-CoV-2 and other coronaviruses, Staphylococcus aureus, Acinetobacter baumannii, and house dust mite allergen—suggesting a path toward a universal respiratory vaccine, with human safety trials planned next.
Researchers at the University of Florida have developed a promising universal cancer vaccine using mRNA technology that stimulates the immune system to attack various tumors, especially when combined with immune checkpoint inhibitors, showing strong results in mice and paving the way for future human trials.
Researchers at the University of Florida have developed a promising experimental mRNA-based vaccine that could lead to a universal cancer vaccine, boosting the immune system to fight various cancers and potentially replacing traditional treatments like surgery and chemotherapy. The vaccine works by stimulating immune responses, including increasing PD-L1 proteins on cancer cells, making tumors more vulnerable to immune attack. While still in early stages and tested in mice, this approach could revolutionize cancer treatment if successful in humans.
A study shows that a generalized mRNA vaccine can boost the immune response against various tumors in mice, especially when combined with immunotherapy drugs, suggesting a potential pathway toward a universal cancer vaccine that activates the immune system broadly rather than targeting specific cancer types.
Scientists at UC Riverside have developed a new RNA-based vaccine strategy that targets a part of the viral genome common to all strains of a virus, potentially eliminating the need for annual vaccine updates. The vaccine has been shown to be effective against any strain of a virus and can be safely used by babies or the immunocompromised. It relies on small, silencing RNA molecules to weaken the virus and boost the body's immune response, making it suitable for a broad spectrum of people. The researchers believe this strategy could lead to a one-and-done vaccine for various viruses, including influenza and respiratory infections, and may be applicable to viruses like dengue, SARS, and COVID.
An mRNA-based flu vaccine that targets a conserved part of the hemagglutinin protein's stem, which doesn't evolve as quickly, is now in a phase I clinical trial. The vaccine is designed to offer long-lasting protection against a broad range of influenza viruses and could eliminate the need for annual development of seasonal influenza vaccines. The trial will test safety and efficacy in a small number of people, and if successful, could be a major public health achievement.
Scientists at the U.S. National Institute of Allergy and Infectious Diseases have made a 'major step forward' in the search for a universal flu vaccine. The new vaccine focuses on the 'stem' of the protein, which is sufficiently similar between different strains, offering protection against all strains. The vaccine appeared to be safe and produced a robust immune response that lasted over a year. The next stage will be to carry out clinical trials to see if such a vaccine actually protects people from flu and extend it to cover influenza type B, too. If successful, a universal vaccine could be available in five to ten years.